Headquartered in Aliso Viejo, CA Fiscal year ends December NYSE: GKOS glaukos.com
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops and commercializes dropless therapies for glaucoma, corneal disorders and retinal diseases.
The company pioneered Micro-Invasive Glaucoma Surgery (MIGS) with its iStent devices, first launched in 2012. It sells glaucoma products in the U.S. and internationally.
Its newer growth drivers are:
- iDose TR, a long-duration intracameral procedural pharmaceutical that delivers glaucoma drug therapy inside the eye, launched in 2024.
- Epioxa, an FDA-approved epithelium-on corneal cross-linking therapy for keratoconus, commercially available since March 2026.
Through its Corneal Health franchise, Glaukos also markets the iLink bio-activated corneal cross-linking therapy.
Its pipeline spans five platforms: iStent micro-scale surgical devices, iDose sustained-release pharmaceuticals, iLink bio-activated pharmaceuticals, iLution transdermal pharmaceuticals, and Retina XR bio-erodible sustained-release pharmaceuticals. Key programs include:
- iDose TREX and iDose TRIO
- iStent infinite for mild-to-moderate glaucoma
- PRESERFLO MicroShunt
- iLution Blepharitis
- GLK-401 for wet AMD
- GLK-901 (RO-104), a tri-specific biologic licensed from RevOpsis Therapeutics Updated
Glaukos just turned profitable on an adjusted basis for the first time after eight straight quarters of losses, and management guided to $1 billion in preliminary 2027 sales. The iDose TR and Epioxa launches are what flipped the model.
Kimberly-Clark is absorbing one of the most recognizable brand portfolios in consumer health, and the deal reshapes what investors own across three different indexes at once. What happens to your dividend income…
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops and commercializes dropless therapies for glaucoma, corneal disorders and retinal diseases.
24/7 Wall St.'s 12-month price target for GKOS is $287.83, rated Buy. The Wall Street consensus target is $243.92. GKOS price prediction →
